Pfizer maintains active strategic collaborations and licensing agreements incorporating CRISPR and related gene-editing technologies to advance its research and development pipeline for rare genetic disorders and specialized therapeutic areas. While Pfizer conducts much of its internal biologics research, it has historically partnered with specialized gene-editing pioneers—including collaborative agreements with companies like Beam Therapeutics—to leverage cutting-edge base-editing and CRISPR-associated technologies for next-generation medicine development.